Capital raising: the routes open to a listed company

By Reto Hediger Published 11 August 2026 Last reviewed 11 August 2026

Capital raising for a listed company is a different exercise from raising money for a private one. A public issuer has a traded price, a shareholder register, a regulator and a listing rulebook, and those four facts decide which routes are open to it: a pre-emptive offer, a placing, a registered offering, a convertible instrument, or a facility drawn over time.

Key takeaways

The routes open to a listed company assume an existing public float. If the company is private, none of the listed-company structures are available to it, and the advice it needs comes from a different market.
Four facts decide what is available. Free float and average daily traded value; prospectus or shelf eligibility; the capacity already authorised by shareholders; and how much dilution the board will accept.
Speed comes from preparation, not negotiation. An issuer with a live authority and an effective shelf can move in days. One without either is on a meeting timetable no counterparty can shorten.
Cost has three layers. Transaction fees, the discount at which stock clears, and permanent dilution. Only the first arrives as an invoice, and it is usually the smallest.

Before you read on

If the company is not listed, this is the wrong page. Every structure here settles in listed stock and prices against a traded market. A private company raising a seed, growth or venture-debt round is doing something genuinely different, and nothing below will translate. What follows assumes a live listing, or a listing process already under way.

The routes a listed board actually considers

A pre-emptive offer, called a rights issue or an open offer depending on the market, offers new stock to existing holders in proportion to their holdings. It is the fairest route and the slowest, and it needs a shareholder base willing and able to write cheques.

A placing or private placement sells new stock to selected investors without offering it to everyone. It is fast, it uses capacity the board already has, and it dilutes the holders who were not invited. Most markets constrain it with a capacity limit, a discount limit, or both.

A registered offering, whether marketed or taken as a registered direct, sells stock off an effective registration statement so that a non-affiliate investor receives freely tradable shares at closing. It requires shelf eligibility, and that eligibility is the single most valuable asset a small listed company can maintain.

A convertible instrument defers the equity decision. The issuer takes cash now and issues stock later at a price set either at signing or by formula. It suits a company expecting a re-rating and it punishes one whose price falls, which is why the protective terms matter more than the headline.

An equity facility, whether a standby, committed or subscription facility, gives the issuer the right to draw capital in tranches over a period. It converts a single financing decision into a series of small ones, at the cost of a running dilution and an ongoing relationship.

The four facts that decide which are open

Start with float and traded volume. A facility or a convertible sized far above what the market trades in a month cannot be exited by the investor without moving the price, so it will either be refused or priced for that risk. Average daily traded value is the number that sets realistic size, not market capitalisation.

Then shelf or prospectus eligibility. In the United States an effective Form S-3 shelf allows an offering to be priced and closed quickly, and a public float below US$75 million brings in the baby-shelf cap under General Instruction I.B.6, which limits primary sales to one-third of public float in any 12-month period. Elsewhere the equivalent question is whether a prospectus is required to admit the new shares.

Then authorised capacity. Almost every market outside the United States runs on a general mandate or authority to allot granted by shareholders and measured as a percentage of shares in issue. Exhausting it converts a two-week transaction into a two-month one. The market pages set out the position venue by venue, from the 20% Hong Kong general mandate to the SGX mandate and discount cap and the Norwegian board authorisation.

Then dilution tolerance. This is a board judgement, not a calculation, but it should be made against the arithmetic rather than against a feeling. The worked examples show how far the same raise can travel under different pricing terms.

The routes compared

Capital raising routes for a listed company compared
Route	Who can buy	What must exist first	Typical constraint
Pre-emptive offer	All existing holders	Offer document or prospectus	Time, and take-up risk
Placing or private placement	Selected investors	Unused capacity under the mandate	Capacity and discount limits
Registered offering	Investors in the offering	An effective registration statement	Form eligibility and the baby-shelf cap
Convertible instrument	The subscribing investor	Reserved shares and conversion terms	Pricing formula and dilution
Equity facility	The facility provider	Registration or resale route for each tranche	Traded volume, drawdown by drawdown
Structural comparison only. Not an offer, a quote, or a rate card.

Capital raising services, advisers and capital providers

Three different things are sold under the same phrase, and confusing them wastes months. A corporate finance adviser or capital raising consultant helps prepare the company and runs a process; it does not supply the money. A placement agent or broker-dealer is licensed to solicit investors and place securities; in several structures that role is a regulatory requirement rather than a preference. A capital provider subscribes for the securities with its own capital and appears on the register.

Issuer Financing is the third of those. We are a capital provider to listed and pre-listing companies. We do not provide broker-dealer, investment-banking or investment-advisory services, and nothing on this site is a recommendation about what any issuer should do. An issuer will normally still need counsel, and for a marketed offering an agent as well.

When the shareholder needs the money, not the company

Every route above issues new securities and dilutes existing holders. Where the requirement actually sits with a founder or substantial holder rather than the company, a loan secured on shares already owned issues nothing and leaves the register unchanged. A separate market covers that: securities-backed lending against a listed shareholding (a site under common ownership with this one), Lombard credit for private-wealth borrowers (a site under common ownership with this one) and stock loans against HKEX-listed shares (a site under common ownership with this one).

The order to do it in

Establish the capacity and the eligibility before you talk to anyone about size. Agree internally what dilution is acceptable and what the money is for, in that order, because the second answer often changes the first. Then approach counterparties with a specific proposition rather than a general enquiry, because a board that knows its own constraints gets better terms than one still discovering them.

Then read the resale side. Whether the securities issued can be sold, and when, is the question that most often stalls a transaction after signing: see Rule 144, S-3 shelf registration and the instrument pages on the instruments hub. If you would rather compress all of that into one conversation, check the eligibility test and then send the listing and the capacity left.

General information, not legal advice. This page describes securities-law concepts, listing rules and financing structures in general terms, and those rules differ by jurisdiction and change. Form eligibility, capacity limits and the availability of any exemption depend on the issuer's own facts. Take advice from qualified securities counsel in the relevant jurisdiction before acting.

Capital raising for listed companies: frequently asked questions

Can a private company use these structures?

No. Every structure described here depends on the existence of a traded public price and a listed security. A PIPE transaction, a registered direct offering, an at-the-market programme and an equity facility all price against the market and settle in listed stock. A private company raising equity or venture debt is doing something different and should talk to advisers who work in that market.

What is the fastest way for a listed company to raise capital?

Usually a placing to institutions or a private placement to a named investor, because neither requires a shareholder meeting when capacity already exists. Where the issuer has an effective shelf registration statement, a registered direct offering can be almost as quick and leaves the investor with freely tradable stock. Speed is a function of what is already in place, which is why the preparation matters more than the negotiation.

How much can a listed company raise without a shareholder vote?

It depends entirely on the listing venue. Capacity is expressed as a general mandate or authority to allot, commonly a percentage of shares in issue, and the percentage differs by market. On Nasdaq the binding constraint is different again: shareholder approval is required before a 20% Issuance priced below the Minimum Price under Listing Rule 5635(d). The number should be established before a size is discussed.

Do we need a bank or a broker to raise capital?

For a marketed offering, yes: a registered broker-dealer normally acts as placement agent or underwriter, and in some structures that role is a regulatory requirement rather than a choice. For a privately negotiated subscription with a capital provider, the transaction is between the issuer and the investor. Issuer Financing is a capital provider and does not provide broker-dealer, investment-banking or investment-advisory services.

What does raising capital as a listed company cost?

There are three cost layers and only one of them appears on an invoice. There are transaction costs, meaning agent fees, legal fees, registration and exchange fees. There is the pricing cost, meaning the discount at which new stock clears. And there is the dilution cost, which is the permanent reduction in each existing holder's share of the company. Boards routinely optimise the first and are surprised by the third.